These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 2905529)

  • 61. [Psychotropic drugs as tools for clinical research into schizophrenia (author's transl)].
    Beckmann H
    Fortschr Neurol Psychiatr Grenzgeb; 1978 Oct; 46(10):564-77. PubMed ID: 29831
    [TBL] [Abstract][Full Text] [Related]  

  • 62. History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia.
    Madras BK
    J Hist Neurosci; 2013; 22(1):62-78. PubMed ID: 23323533
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.
    Joyce JN; Goldsmith SG; Gurevich EV
    J Psychiatr Res; 1997; 31(2):197-217. PubMed ID: 9278186
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Could the interaction of neuroleptics with calmodulin be an "explanation" of the psychotropic effects?
    Lejoyeux M; Maziere JC
    Encephale; 1991; 17(1):11-5. PubMed ID: 1688272
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Dopaminergic receptor activity and the evolution of schizophrenia].
    Fodoreanu L
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1985; 30(2):131-4. PubMed ID: 2864729
    [No Abstract]   [Full Text] [Related]  

  • 66. Neuroleptics and psychic indifference: a review.
    Healy D
    J R Soc Med; 1989 Oct; 82(10):615-9. PubMed ID: 2572700
    [No Abstract]   [Full Text] [Related]  

  • 67. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Positron tomographic quantitation of neuroreceptors in human brain in vivo--with special reference to the D2 dopamine receptors in caudate nucleus.
    Gjedde A; Wong DF
    Neurosurg Rev; 1987; 10(1):9-18. PubMed ID: 2959876
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The dopamine hypothesis of schizophrenia: current status, future prospects.
    Willner P
    Int Clin Psychopharmacol; 1997 Nov; 12(6):297-308. PubMed ID: 9547131
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Psychotropic drugs: mechanism of action at the neurotransmitter level.
    Preziosi P; Nisticò G
    Int J Clin Pharmacol Biopharm; 1977 Nov; 15(11):497-518. PubMed ID: 22501
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reversibility of hemodynamic hypofrontality in schizophrenia.
    Geraud G; Arné-Bès MC; Güell A; Bes A
    J Cereb Blood Flow Metab; 1987 Feb; 7(1):9-12. PubMed ID: 2879850
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [The place of amisulpride in the atypical neuroleptic class].
    Perrault G; Schoemaker H; Scatton B
    Encephale; 1996 Jun; 22 Spec No 2():3-8. PubMed ID: 8767034
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
    Seeman P; Chau-Wong M; Tedesco J; Wong K
    Proc Natl Acad Sci U S A; 1975 Nov; 72(11):4376-80. PubMed ID: 1060115
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dopamine in schizophrenia: a review and reconceptualization.
    Davis KL; Kahn RS; Ko G; Davidson M
    Am J Psychiatry; 1991 Nov; 148(11):1474-86. PubMed ID: 1681750
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The development of new drugs for the treatment of schizophrenia.
    Cookson J
    Br J Hosp Med; 1987 Dec; 38(6):542-8. PubMed ID: 2893648
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Alpha7 nicotinic cholinergic neuromodulation may reconcile multiple neurotransmitter hypotheses of schizophrenia.
    Bencherif M; Stachowiak MK; Kucinski AJ; Lippiello PM
    Med Hypotheses; 2012 May; 78(5):594-600. PubMed ID: 22336089
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Biogenic amines and schizophrenia].
    Schöpf J
    Schweiz Med Wochenschr; 1975 Sep; 105(38):1201-9. PubMed ID: 1061994
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Differential effects of D2- and D4-blocking neuroleptics on the procedural learning of schizophrenic patients.
    Bédard MA; Scherer H; Delorimier J; Stip E; Lalonde P
    Can J Psychiatry; 1996 Sep; 41(7 Suppl 1):S21-4. PubMed ID: 8884048
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D
    Schizophr Bull; 1988; 14(2):255-68. PubMed ID: 2904694
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mayo Seminars in Psychiatry: dopamine and schizophrenia--a review.
    Fredrickson P; Richelson E
    J Clin Psychiatry; 1979 Sep; 40(9):399-405. PubMed ID: 39063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.